Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Nat Microbiol ; 3(11): 1255-1265, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30349083

RESUMEN

To minimize the impact of antibiotics, gut microorganisms harbour and exchange antibiotics resistance genes, collectively called their resistome. Using shotgun sequencing-based metagenomics, we analysed the partial eradication and subsequent regrowth of the gut microbiota in 12 healthy men over a 6-month period following a 4-day intervention with a cocktail of 3 last-resort antibiotics: meropenem, gentamicin and vancomycin. Initial changes included blooms of enterobacteria and other pathobionts, such as Enterococcus faecalis and Fusobacterium nucleatum, and the depletion of Bifidobacterium species and butyrate producers. The gut microbiota of the subjects recovered to near-baseline composition within 1.5 months, although 9 common species, which were present in all subjects before the treatment, remained undetectable in most of the subjects after 180 days. Species that harbour ß-lactam resistance genes were positively selected for during and after the intervention. Harbouring glycopeptide or aminoglycoside resistance genes increased the odds of de novo colonization, however, the former also decreased the odds of survival. Compositional changes under antibiotic intervention in vivo matched results from in vitro susceptibility tests. Despite a mild yet long-lasting imprint following antibiotics exposure, the gut microbiota of healthy young adults are resilient to a short-term broad-spectrum antibiotics intervention and their antibiotics resistance gene carriage modulates their recovery processes.


Asunto(s)
Antibacterianos/farmacología , Fenómenos Fisiológicos Bacterianos , Microbioma Gastrointestinal/efectos de los fármacos , Microbioma Gastrointestinal/fisiología , Adolescente , Adulto , Bacterias/clasificación , Bacterias/efectos de los fármacos , Bacterias/genética , Bacterias/aislamiento & purificación , Biodiversidad , Farmacorresistencia Bacteriana/genética , Heces/microbiología , Genes Bacterianos , Voluntarios Sanos , Humanos , Masculino , Metagenómica , Factores de Virulencia/genética , Adulto Joven
2.
BMC Endocr Disord ; 18(1): 60, 2018 Sep 04.
Artículo en Inglés | MEDLINE | ID: mdl-30180841

RESUMEN

BACKGROUND: Intestinal bacteria influence bone remodeling in rodents, and antibiotic manipulation of the rodent gut microbiota increases bone formation and prevents ovariectomy-induced bone loss. In theory, these effects may be mediated by changes in sex hormone biotransformation in the gut, gut serotonin secretion or nutrition-induced secretion of glucagon-like peptide 2 (GLP-2) and glucose-dependent insulinotropic hormone (GIP). Antibiotics change the human gut microbiota, but the effect of antibiotic treatment on human bone turnover is unknown. METHODS: We analyzed serum levels of bone turnover markers, serotonin, GLP-2 and sex hormones before, immediately after, and eight, 42 and 180 days after a 4-day per oral antibiotic cocktail (vancomycin 500 mg, gentamycin 40 mg and meropenem 500 mg once-daily) in twelve healthy adult males. Fasting and meal-stimulated procollagen type I amino-terminal propeptide (P1NP), C-telopeptide of type I collagen (CTX) and osteocalcin levels were measured. RESULTS: While the antibiotic course reduced the stool abundance and composition of anaerobic bacteria as confirmed by cultivation studies, neither short nor long-term alterations in serum P1NP, CTX and osteocalcin were observed. Furthermore, we did not observe any changes in levels of serum GLP-2, serotonin or sex hormones. CONCLUSION: Eradication of anaerobic bacteria from healthy adult males had no effect on serum bone turnover markers.


Asunto(s)
Antibacterianos/farmacología , Remodelación Ósea/efectos de los fármacos , Remodelación Ósea/fisiología , Osteogénesis/efectos de los fármacos , Osteogénesis/fisiología , Adulto , Biomarcadores/sangre , Colágeno Tipo I/sangre , Microbioma Gastrointestinal/efectos de los fármacos , Microbioma Gastrointestinal/fisiología , Receptor del Péptido 2 Similar al Glucagón/sangre , Humanos , Masculino , Osteocalcina/sangre , Péptidos/sangre
3.
J Diabetes Complications ; 31(5): 918-927, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28238556

RESUMEN

AIM: To evaluate the effects of bile acid sequestrants (BASs) versus placebo, no intervention or active comparators on glycemic control in type 2 diabetes. METHODS: Data were retrieved and a systematic review with meta-analyses was performed. We evaluated bias control and subgroup and sensitivity analyses were performed to evaluate heterogeneity and bias. RESULTS: We included 17 trials with a total of 2950 patients randomized to BASs (colesevelam or colestimide) versus placebo, no intervention, statins or sitagliptin. Random-effects meta-analysis showed that patients randomized to BASs had a lower hemoglobin A1c at the end of treatment compared with the control group (mean difference-0.55%; 95% confidence interval-0.64 to -0.46). Analysis of trials with low risk of bias in all domains confirmed the findings. Data on adverse events were limited. There were no differences between trials stratified by the control group and no evidence of publication bias or small study effects. CONCLUSIONS: Our analyses found that BAS treatment improves glycemic control. The size of the effect was clinically relevant and despite limited safety data, our findings support the inclusion of BASs in current diabetes management algorithms for type 2 diabetes.


Asunto(s)
Ácidos y Sales Biliares/antagonistas & inhibidores , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hiperglucemia/prevención & control , Hipoglucemia/prevención & control , Hipoglucemiantes/uso terapéutico , Secuestrantes/uso terapéutico , Ácidos y Sales Biliares/efectos adversos , Clorhidrato de Colesevelam/efectos adversos , Clorhidrato de Colesevelam/uso terapéutico , Diabetes Mellitus Tipo 2/sangre , Epiclorhidrina/efectos adversos , Epiclorhidrina/uso terapéutico , Hemoglobina Glucada/análisis , Humanos , Hipoglucemia/inducido químicamente , Hipoglucemiantes/efectos adversos , Imidazoles/efectos adversos , Imidazoles/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Reproducibilidad de los Resultados , Resinas Sintéticas/efectos adversos , Resinas Sintéticas/uso terapéutico , Secuestrantes/efectos adversos
5.
PLoS One ; 10(11): e0142352, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26562532

RESUMEN

OBJECTIVE: The gut microbiota has been designated as an active regulator of glucose metabolism and metabolic phenotype in a number of animal and human observational studies. We evaluated the effect of removing as many bacteria as possible by antibiotics on postprandial physiology in healthy humans. METHODS: Meal tests with measurements of postprandial glucose tolerance and postprandial release of insulin and gut hormones were performed before, immediately after and 6 weeks after a 4-day, broad-spectrum, per oral antibiotic cocktail (vancomycin 500 mg, gentamycin 40 mg and meropenem 500 mg once-daily) in a group of 12 lean and glucose tolerant males. Faecal samples were collected for culture-based assessment of changes in gut microbiota composition. RESULTS: Acute and dramatic reductions in the abundance of a representative set of gut bacteria was seen immediately following the antibiotic course, but no changes in postprandial glucose tolerance, insulin secretion or plasma lipid concentrations were found. Apart from an acute and reversible increase in peptide YY secretion, no changes were observed in postprandial gut hormone release. CONCLUSION: As evaluated by selective cultivation of gut bacteria, a broad-spectrum 4-day antibiotics course with vancomycin, gentamycin and meropenem induced shifts in gut microbiota composition that had no clinically relevant short or long-term effects on metabolic variables in healthy glucose-tolerant males. TRIAL REGISTRATION: clinicaltrials.gov NCT01633762.


Asunto(s)
Antibacterianos/farmacología , Hormonas Gastrointestinales/metabolismo , Microbioma Gastrointestinal/efectos de los fármacos , Glucosa/metabolismo , Adolescente , Adulto , Antibacterianos/efectos adversos , Antibacterianos/metabolismo , Carga Bacteriana , Glucemia/metabolismo , Diarrea/inducido químicamente , Ayuno/sangre , Heces/química , Heces/microbiología , Hormonas Gastrointestinales/sangre , Gentamicinas/efectos adversos , Gentamicinas/metabolismo , Gentamicinas/farmacología , Humanos , Insulina/sangre , Masculino , Meropenem , Periodo Posprandial , Tienamicinas/efectos adversos , Tienamicinas/metabolismo , Tienamicinas/farmacología , Factores de Tiempo , Resultado del Tratamiento , Vancomicina/efectos adversos , Vancomicina/metabolismo , Vancomicina/farmacología , Adulto Joven
6.
J Clin Endocrinol Metab ; 100(2): 636-43, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25415176

RESUMEN

CONTEXT: Ketone bodies are substrates during fasting and when on a ketogenic diet not the least for the brain and implicated in the management of epileptic seizures and dementia. Moreover, D-ß-hydroxybutyrate (HOB) is suggested to reduce blood glucose and fatty acid levels. OBJECTIVES: The objectives of this study were to quantitate systemic, cerebral, and skeletal muscle HOB utilization and its effect on energy metabolism. DESIGN: Single trial. SETTING: Hospital. PARTICIPANT: Healthy post-absorptive males (n = 6). INTERVENTIONS: Subjects were studied under basal condition and three consecutive 1-hour periods with a 3-, 6-, and 12-fold increased HOB concentration via HOB infusion. MAIN OUTCOME MEASURES: Systemic, cerebral, and skeletal muscle HOB kinetics, oxidation, glucose turnover, and lipolysis via arterial, jugular, and femoral venous differences in combination with stable isotopically labeled HOB, glucose, and glycerol, infusion. RESULTS: An increase in HOB from the basal 160-450 µmol/L elicited 14 ± 2% reduction (P = .03) in glucose appearance and 37 ± 4% decrease (P = .03) in lipolytic rate while insulin and glucagon were unchanged. Endogenous HOB appearance was reduced in a dose-dependent manner with complete inhibition at the highest HOB concentration (1.7 mmol/L). Cerebral HOB uptake and subsequent oxidation was linearly related to the arterial HOB concentration. Resting skeletal muscle HOB uptake showed saturation kinetics. CONCLUSION: A small increase in the HOB concentration decreases glucose production and lipolysis in post-absorptive healthy males. Moreover, cerebral HOB uptake and oxidation rates are linearly related to the arterial HOB concentration of importance for modifying brain energy utilization, potentially of relevance for patients with epileptic seizures and dementia.


Asunto(s)
Ácido 3-Hidroxibutírico/farmacología , Corteza Cerebral/metabolismo , Metabolismo Energético/fisiología , Cuerpos Cetónicos/metabolismo , Músculo Esquelético/metabolismo , Ácido 3-Hidroxibutírico/farmacocinética , Adulto , Glucemia/metabolismo , Corteza Cerebral/efectos de los fármacos , Metabolismo Energético/efectos de los fármacos , Humanos , Insulina/sangre , Masculino , Músculo Esquelético/efectos de los fármacos , Adulto Joven
7.
J Appl Physiol (1985) ; 103(2): 425-31, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17463304

RESUMEN

The consumption of nonsteroidal anti-inflammatory drugs (NSAIDs) is widespread among athletes when faced with muscle soreness or injury, but the effects of NSAIDs on satellite cell activity in humans are unknown. To investigate this, 14 healthy male endurance athletes (mean peak oxygen consumption 62 ml x kg(-1) x min(-1)) volunteered for the study, which involved running 36 km. They were divided into two groups and received either 100 mg indomethacin per day or placebo. Muscle biopsies collected before the run and on days 1, 3, and 8 afterward were analyzed for satellite cells by immunohistochemistry with the aid of neural cell adhesion molecule (NCAM) and fetal antigen-1 (FA1) antibodies. Muscle biopsies were also collected from untrained individuals for comparison. Compared with preexercise levels, a 27% increase in the number of NCAM+ cells was observed on day 8 postexercise in the placebo group (P < 0.05), while levels remained similar at all time points in the NSAID group. No change was seen in the proportion of FA1+ cells, although lower levels were found in the muscle of endurance-trained athletes compared with untrained individuals (P < 0.05). These results suggest that ingestion of anti-inflammatory drugs attenuates the exercise-induced increase in satellite cell number, supporting the role of the cyclooxygenase pathway in satellite cell activity.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Inhibidores de la Ciclooxigenasa/farmacología , Ejercicio Físico/fisiología , Células Satélite del Músculo Esquelético/efectos de los fármacos , Células Satélite del Músculo Esquelético/fisiología , Adulto , Antiinflamatorios no Esteroideos/uso terapéutico , Biomarcadores/metabolismo , Biopsia , Proteínas de Unión al Calcio , Proliferación Celular/efectos de los fármacos , Inhibidores de la Ciclooxigenasa/uso terapéutico , Femenino , Humanos , Indometacina/farmacología , Indometacina/uso terapéutico , Péptidos y Proteínas de Señalización Intercelular/fisiología , Masculino , Proteínas de la Membrana/fisiología , Músculo Esquelético/citología , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/fisiología , Moléculas de Adhesión de Célula Nerviosa/fisiología , Prostaglandina-Endoperóxido Sintasas/fisiología , Regeneración/fisiología , Carrera , Células Satélite del Músculo Esquelético/citología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA